W hile evidence demonstrating the existence of thyroidspecific Ags is pervasive, the evidence that these tissue-specific Ags become targets of antitumor-specific immunity is absent. For example, numerous studies have suggested that thyroglobulin, thyrotropin receptor, and thyroid peroxidase may serve as Ags during thyroid autoimmune disease (1); however, it is unknown whether these Ags represent major targets in anticancer host responses. This is important because targeting tissue-specific Ags in the thyroid may be analogous to the self protein-directed antimelanoma immunotherapies used in patients in which autoimmune depigmentation (vitiligo) can result from targeting such self molecules (2) . Similar treatments in thyroid cancer patients may cause autoimmune thyroid disease, the leading cause of hypothyroidism in the U.S. Consequently, we have been interested in determining whether thyroid cancers express tumorspecific targets distinguishable from self that may limit immunization-induced autoimmune disease. Because differentiated thyroid carcinomas originating from the thyroid epithelium frequently express tumor-specific rearranged during transfection/papillary thyroid carcinoma (RET/PTC) 3 fusion proteins (3), we hypothesized that inflammation along with immune responses to these unique Ags during the early stages of thyroid transformation may lead to immune recognition (4) and, by directing immune cells to target RET/PTC proteins, may provide an ideal antitumor therapy. To begin to address such a hypothesis, we set out to measure the nature of RET/PTC immunogenicity. Papillary thyroid cardcinoma (PTC) is a relatively rare cancer, with an incidence of 3 of 100,000 (5); however, it is the most prevalent endocrine tumor, comprising nearly 80% of all thyroid malignancies (1) . Nearly 60% of differentiated thyroid carcinomas of the epithelium, including PTC, is characterized by the frequent expression of one or more members of a family of unique oncogenic fusion proteins resulting from chromosomal inversions or translocations (6, 7) . In a majority of PTC, the tyrosine kinase domain (TKD) of the c-RET or tropomyosin receptor kinase protooncogenes and the amino-terminal portion of one of several widely expressed genes are juxtaposed to form a hybrid protein with ectopic constitutive tyrosine kinase activity in the cytosol of thyroid epithelial cells (3) . The family of 10 fusion genes associated with c-RET rearrangement is collectively known as RET/PTC. One member of this fusion gene family, RET/PTC3 (RP3), is formed following a paracentric inversion involving c-RET and RFG/ ARA70 (8, 9) . Of note, RP3 can be found in thyroid tissue from patients with the chronic thyroid inflammatory disease, Hashimoto's thyroiditis (10, 11) . Likewise, somatic rearrangement of c-RET has been observed in irradiated human thyroid tissue grafts in SCID mice, supporting the notion that ionizing radiation is an etiologic agent for thyroid cancer (12) . Tumor progression to advanced stages (poorly differentiated or undifferentiated thyroid cancer) in humans and in animal models does not correlate with persistent RET/PTC expression (4, 13, 14) , a finding inconsistent with other models of multistep carcinogenesis (15) .
In human cancers, mutant proteins involved in cellular transformation harbor structural abnormalities, including rearranged coding regions, internal deletions, point mutations, or viral proteins resulting from insertional mutagenesis. Altered gene products encoding novel fusion oncoproteins may represent candidate tumorspecific Ags capable of eliciting immune recognition and may be ideal targets for tumor immunotherapy because their expression is required for transforming activity. Although published data suggest a role for fusion gene products in human tumor-specific immune responses (16 -19) , there is no clear understanding of whether fusion proteins represent immunogenic epitopes enabling tumor rejection.
The relationship between lymphocytic infiltrates and thyroid cancer, particularly PTC, in humans is well documented (20, 21) . The observation that lymphocytic infiltration of the thyroid coexists with cancer suggests that Ags expressed by tumor cells are responsible for inducing an antitumor immune response (22) . We hypothesized that reactivity to transformed thyroid cells or occult tumors may lead to oncoprotein-reactive lymphocyte accumulation in the thyroid. In this study, we have investigated the immunogenic capability of the RP3 fusion protein when presented in the presence of a strong adjuvant or when expressed in preneoplastic thyroid tissue or invasive thyroid tumor grafts to define its role as an antigenic nonself protein and thyroid-specific tumor Ag. Although the RP3 protein represents the fusion of two widely expressed self proteins to which immunological tolerance is most likely induced, we find that fusion confers a unique immunogenic capability upon the RP3 protein. The results of these studies may help to define novel strategies for the immunotherapeutic targeting of oncoproteins at early stages of neoplastic progression.
Materials and Methods

Mice
RP3 transgenic mice (3209 line) have been previously described (23) and have subsequently been backcrossed for Ͼ10 generations to endotoxinresistant C3H/HeJ mice using polymorphism selection. Homozygous RP3 mice were crossed with C57BL/6-Tpr53 mice and double heterozygotes crossed to generate RP3 p53Ϫ/Ϫ mice (4). Progeny were genotyped using RP3-and p53-specific primers in a standard DNA amplification reaction (PCR), as previously described (4) . Six-to 8-wk-old C57BL/6J-Prkdc scid / SzJ (C57BL/6 SCID) mice (The Jackson Laboratory, Bar Harbor, ME) were used for the growth of tumor tissue and to determine specimen viability. Female C3H/HeJ and male B6C3F1/J, 6 -8 wk old, were obtained from The Jackson Laboratory.
Expression plasmid construction
Human (h) or mouse (m) RP3, mouse Ret TKD , or control coding sequence T cell locus 1 (Tcl1) were cloned into the pET-29a ϩ protein expression vector (Novagen, Madison, WI) adjacent to a COOH-terminal hexahistidine tag to facilitate protein purification, and a selectable kanamycin marker to aid in positively selecting transfectants. The hRP3 gene sequence was amplified from the construct previously described for the generation of RP3 transgenic mice (23) . The amino-terminal gene segment of mouse Rfg/Ara70 (AF159461) and mouse Ret TKD (AF209436) were amplified using endonuclease restriction site-linked gene-specific primers (SalI-linked Rfg/Ara70 forward primer, GTC/GAC/GTC/GAC/ATG/AAC/ACA/TCC/ CTG/GAA/CAG/AGT/GG; BamHI-linked Rfg/Ara70 reverse primer, CGG/ GAT/CCT/CCT/GAC/TAT/TCT/CTG/AAG/TCT/GTT/TTG/G; BamHI-linked Ret forward primer, CTG/GAT/CCA/AAG/TGG/GAA/TTT/CCT/CGG/ AAG/AAC; and NotI-linked Ret reverse primer, GTC/GCG/GCC/GCT/TAG/ CTA/TCA/AAT/GTG/TCC/ATT/AAT/TTT/GC). Partial and complete BamHI digestion of Rfg/Ara70 and c-RET genes, respectively, was required for proper ligation of full-length RP3. All constructed plasmids were verified by sequence analysis.
Recombinant proteins and peptides
To generate recombinant protein, plasmid constructs were introduced into BLR (DE3) pLysS-competent cells (Novagen, Madison, WI), and protein expression was induced in kanamycin-resistant cells using isopropyl B-Dthiogalactopyranoside at a final concentration of 1 mM for 4 h at 37°C. Cells were lysed in denaturing buffer (8 M urea, 100 mM NaH 2 PO 4 , 10 mM Tris-Cl, pH 8.0), cellular debris were removed by ultracentrifugation at 45,000 rpm for 30 min at 4°C, and hexahistidine affinity-tagged proteins first bound to a Ni-NTA agarose column (Qiagen, Valencia, CA) were then eluted under denaturing conditions using an imidazole gradient. A second round of column chromatography was performed again using a Ni-NTA agarose column to ensure high protein purity. Recombinant proteins were dialyzed against PBS, 0.22 m filtered, and analyzed for the presence of the 68-kDa rhRP3, the 75-kDa rmRP3, the 45-kDa rmRet TKD , or the 14-kDa rTcl1 protein (negative control) on SDS-PAGE by Coomassie blue staining and, in parallel, by Western blot analysis using polyclonal rabbit anti-RET (C-19) and (C-20) (Santa Cruz Biotechnology, Santa Cruz, CA) or anti-Tcl1 Abs, as previously described (23) . Proteins were verified to be endotoxin free using the endotoxin neutralizing protein from Limulus polyphemus (Sigma-Aldrich, St. Louis, MO). An RP3 peptide (KQTLE NSQEDPKWEF) specific for the fusion breakpoint region was synthesized by the Thomas Jefferson University Peptide Synthesis Facility. This sequence was chosen based on its high MHC-predicted binding coefficient, as measured by an established algorithm (http://syfpeithi.bmiheidelberg.com/scripts/MHCServer.dll/home.htm). Peptide scores Ͼ20 were predicted to have significant binding potential.
Viral preparation
Recombinant vaccinia virus was propagated, as previously described (24) . The RP3 construct was cloned into a modified pSC11 plasmid for expression from the vaccinia P 7.5 promoter. RP3 gene sequence was introduced into the vaccinia genome by homologous recombination in CV-1 cells, and recombinant viruses were subsequently triple plaque purified in 143B cells in the presence of 5 mg/ml 5-bromo-2Ј-deoxyuridine (Boehringer Mannheim, Indianapolis, IN). Viral stocks were expanded and titered using 143B HuTK Ϫ cells.
Immunization protocols
Female C3H/HeJ mice, RP3 transgenic mice, or nontransgenic littermates were s.c. immunized in the hind flank with 10 g rhRP3 or rmRP3, 5 g rmRet TKD , or 10 g rTCL (control) protein emulsified in CFA (SigmaAldrich). This injection was followed 1-2 wk later by a second injection of the same material into the same mice (10 g of rRP3, 5 g rmRet TKD , or 10 g rmTcl1 control protein); however, this injection used protein emulsified in IFA (Sigma-Aldrich). For specified experiments, additional controls included injections of PBS in CFA, followed by PBS in IFA (nonimmune mice). One to two weeks following final immunization, lymph node cells (LNC; mandibular, superficial cervical, axillary, lateral axillary, superficial inguinal, mesenteric, and popliteal nodes), spleen cells, and serum were harvested for analysis. For tumor transplant immunization, anesthetized male 6-to 8-wk-old B6C3F1/J or C57BL/6 SCID control mice received 3-mm 3 RP3 p53Ϫ/Ϫ thyroid tumor fragments. Mice were monitored each week for signs of tumor rejection (including reduction in tumor size or stabilization of tumor growth). After 2 mo, LNC and serum were harvested from mice that had rejected tumor fragments.
Lymphoproliferation assays
Single cell suspensions of LNC and/or spleen cells from rRP3-, tumor-, or nonimmunized mice were prepared in RPMI 1640 medium (Invitrogen, Carlsbad, CA) containing 25 M 2-ME, 200 U/ml of penicillin, 200 U/ml of streptomycin, 10 mM L-glutamine, and 10% FBS. For T cell proliferation assays, cells were cultured in 96-well plates (2 ϫ 10 5 cells/well) to which recombinant proteins, RP3-specific peptide, or bacterial control eluates were added at a previously determined optimal concentration of 1 g/ml. Plates were cultured in a 5% CO 2 humidified incubator for 48 h at 37°C and incubated with 1 Ci of [ 3 H]thymidine/well for additional 18 h. Wells were harvested onto nylon filters, and radioactivity was quantified using scintillant in a gamma counter (Beckman Instruments, Palo Alto, CA). Results are expressed in cpm (mean of quadruple wells).
Enzyme-linked immunosorbent assay
Antisera were collected from rhRP3-immune, RP3 p53Ϫ/Ϫ tumor-immune, and nonimmunized mice by collecting blood from the retroorbital sinus, followed by clotting and centrifugation at 14,000 rpm for 5 min. Serum was removed and stored at 4°C. In ELISA, 250 ng of rhRP3 protein was adsorbed overnight to each well of a 96-well microtiter plate at 4°C. Serial dilutions of sera were added to protein-coated wells and incubated at room temperature for 2 h. Plates were washed and incubated with biotin-conjugated horse anti-mouse Ab (1:1000; Vector Laboratories, Burlingame, CA), followed by streptavidin-alkaline phosphatase (1:4000; Southern Biotechnology Associates, Birmingham, AL) and subsequently p-nitrophenyl phosphate solution. Product detection was performed at 405 nm.
Immunoprecipitation assay
A 1/10 dilution of RP3 immune or nonimmune mouse antisera in immunoprecipitation buffer (2% Triton X-100, 5 mM Tris-HCl (pH 7.5), 10 mM NaCl) was bound to protein A-Sepharose beads (Amersham Pharmacia Biotech, Piscataway, NJ) overnight with 10 g of rhRP3, and washed twice with immunoprecipitation buffer and twice with 10 mM Tris-HCl, pH 7.5. Equivalent amounts of rhRP3 protein in 1ϫ SDS loading buffer was resolved using multiple lanes of a 8% SDS-PAGE gel and transferred to Hybond ECL nitrocellulose membrane (Amersham Pharmacia Biotech) for 100 V/h. Membranes were blocked for 1 h in 5% milk-TBST (20 mM Tris-HCl (pH 7.6), 135 mM NaCl, and 1% Tween 20) and cut into individual strips corresponding to the lanes on the original SDS-PAGE gel. Each strip was incubated with a 1/1000 dilution of goat anti-RET (C-19) polyclonal Ab (Santa Cruz Biotechnology) in 5% milk-TBST. After incubation, membranes were treated with HRP-labeled anti-goat IgG (ECL reagent kit; Amersham Pharmacia Biotech) for 30 min at room temperature, according to the manufacturer's protocol. Substrate was added from the ECL reagent kit (Amersham Pharmacia Biotech) and exposed to x-ray film for 1-5 min.
Histological analysis
Thyroid tissues were removed, fixed in 10% Formalin for Ն24 h, and desiccated. Following desiccation, tissue samples were embedded in liquid paraffin and cooled. Paraffin-embedded tissue was cut into 6-M sections and placed on silanized slides (Fisher Scientific, Pittsburgh, PA). After deparaffinizing, the sections were rehydrated through decreasing concentrations of xylene and alcohol and microwaved for 15 min in 100 mM citrate buffer (pH 6.0). Slides were then stained with H&E, dehydrated, fixed, and mounted.
Statistical analysis
Grouped data were compared and analyzed for statistical significance using an independent samples t test (Analyze-it, version 1.65, program add-in for Microsoft Excel; Analyze-It Software, Leeds, U.K.). Groups were considered different when calculated p values were less than 0.05.
Results
RP3 is a nonself protein that stimulates class II-restricted Ag-specific T cell and serological responses
RP3 is a somatically activated, unique protein that consists of two fused self proteins that may encode immunogenic determinants after intracellular Ag processing. To determine the immunogenicity of the RP3 fusion protein, naive C3H/HeJ female mice were immunized with small amounts (10 g) of purified rhRP3 protein in CFA. Two weeks following immunization, LNC were harvested from rhRP3-immunized and mock-immunized mice and cultured with rhRP3 or control proteins to assess T cell proliferative responses in vitro. LNC from naive mice immunized with rhRP3 proliferated in response to rhRP3, but not to an unrelated control protein purified using an identical purification methodology (Fig.  1A) . Flow cytometric analysis identified the predominant proliferating cell population as CD4 ϩ (not shown). Consistent with these data, cell proliferation was significantly inhibited using anti-class II I-A k or I-E k Ab, but not with an isotype control antiserum (Fig.  1B) . Because the novel amino acid sequence of the hRP3 fusion region represents a unique nonself amino acid sequence, a synthetic 15-mer peptide corresponding to this region and selected based on its MHC-binding potential was used for in vitro stimulation. Interestingly, lymphocytes from rhRP3-immunized mice responded only mildly to this synthetic peptide, suggesting that sequences other than the unique fusion region may constitute the natural immunodominant epitopes of RP3 (Fig. 1A) . In contrast to rhRP3-immunized mice, LNC from control C3H/HeJ female mice failed to proliferate significantly above background in response to either rhRP3 protein or to the fusion region peptide (not shown).
The induction of CD4
ϩ T cell responses specific for RP3 suggested that B cell responses might also be stimulated in immunized mice following exogenous protein immunization. To ascertain this, serum was collected from rhRP3-and control-immunized mice, FIGURE 1. RP3-specific lymphoproliferation in wild-type mice. Wildtype C3H/HeJ female mice were immunized s.c. twice with 10 g rhRP3 and adjuvant. One week following final injection, LNC and serum were collected. A, LNC from rhRP3-immunized mice show an in vitro recall proliferative response to rhRP3, but not to an unrelated protein rTcl1 purified using the same methodology, or a synthetic peptide corresponding to the RP3 fusion region. RP3 stimulation is significantly different from controls (p Ͻ 0.02), whereas response to the RP3 breakpoint peptide is not. B, Inhibition of rhRP3-immune LNC proliferation with Abs to MHC class II I-E k or I-A k , but not with an unrelated isotype control Ab. Ab inhibition for each group (specificity) is significantly different from isotype control (p Ͻ 0.001). C, Serum from rhRP3-immunized mice (gray circles) shows reactivity to rhRP3 protein using ELISA. RP3 p53Ϫ/Ϫ tumor-immunized (f) or nonimmunized (‚) mice failed to produce specific Ab reactivity. Data are representative of three independent experiments. Statistical significance was determined by an independent samples t test (Analyze-it). and the development of specific Ab responses was measured using ELISA. Although Ab reactivity to rhRP3 protein was not observed in sera samples from control-immunized mice, reactivity to rhRP3 was appreciable in sera from rhRP3-immunized mice (Fig. 1C) . Additionally, immunoprecipitation results confirmed the specificity of rhRP3-immune sera by precipitation of the 68-kDa rhRP3 protein, in contrast to that of serum from control-immunized naive mice, which lacked rhRP3 reactivity (not shown). Taken together, these data demonstrate that RP3 is immunogenic, eliciting class II-mediated CD4
ϩ LNC proliferation and Ab reactivity following conventional adjuvant-based immunization schemes using small amounts of recombinant protein.
LNC proliferation and cross-reactivity following immunization with mRP3 protein
Because rhRP3 protein immunization of mice induced reactivity to whole RP3 fusion protein, but not fusion region peptide, the possibility existed that the observed RP3 reactivity was a product of a xenogenic response. Although the amino acid sequence of hRP3 and its respective counterparts expressed in mouse are 92% homologous, the immunogenic properties of hRP3 protein in mice may result from the remaining 8% amino acid differences. To address this concern, a mRP3 fusion gene was engineered because such fusions are not known to exist in mouse thyroid tissue. Using specific PCR primers, the amino-terminal portion of the mouse Rfg/Ara70 gene and the TKD of the c-RET proto-oncogene were amplified from adult C3H/HeJ spleen and salivary gland cDNAs, respectively. Subsequently, the two products were juxtaposed and cloned, in frame, into a bacterial expression vector. Because the c-RET tyrosine kinase domain (Ret TKD ) of both mouse and human forms of RP3 contain the highest scoring-predicted immunogenic epitopes, the gene sequence identical with the nonmutated Ret TKD segment of the mRP3 fusion gene was also cloned using the same vector system. rmRP3 and rmRet TKD proteins were produced and purified, and their expression was confirmed by Western blot analysis using a human-mouse cross-reactive Ret TKD -specific Ab (Fig. 2A) . To measure the immunogenicity of the mRP3 protein, naive C3H/HeJ mice were immunized with rmRP3 protein, and 1 wk following final injection in vitro proliferation assays were performed on harvested LNC. Unlike control-immunized LNC that failed to proliferate in response to either protein, lymphocytes from rmRP3-immunized mice proliferated strongly and specifically to rmRP3 (Fig. 2B ) and rhRP3. Similar results were obtained in reciprocal experiments in which rhRP3-immune LNC were stimulated with rmRP3 (Fig. 2B) . These data show that mRP3 and hRP3 proteins are equally immunogenic and that xenogenicity cannot exclusively account for the observed anti-RP3 T and B cell reactivity, suggesting a unique immunological characteristic of the RP3 fusion protein.
To dissect the components of RP3 immunogenicity, we engineered a self protein that is identical with the c-RET portion of the mRP3 molecule (rmRet TKD ). This region also contains a predicted immunogenic self epitope, but lacks the unique fusion region segment of RP3. We next compared the immunogenicity of the RP3 fusion protein to Ret TKD . Interestingly, rmRP3-immune LNC were capable of recognizing the rmRet TKD protein, as measured by lymphocyte proliferation. In addition, proliferation of both rmRP3 and rhRP3-immune LNC occurred in rmRet TKD -stimulated cultures, although to a lesser extent than when these cultures were stimulated with whole mRP3 or hRP3 protein (Fig. 2B) . Neither immune nor nonimmune lymphocytes proliferated well to control recombinant protein. These data indicated that an immunogenic self epitope(s) is encoded within the TKD portion of the RP3 molecule and that the unique breakpoint-specific amino acid sequence may not be essential for anti-RP3 immunity.
Tolerance to the Ret TKD self protein
The above experiments demonstrate the immunogenicity of the mouse Ret TKD when presented as a portion of the fused RP3 protein. Because the Ret TKD is a self protein to which mice should be tolerant, we investigated whether immunization under conditions that would distinguish self from nonself proteins by injecting mice with this nonfused domain of mRP3 is capable of evoking an immune response. Naive mice were immunized with either whole rmRP3 or rmRet TKD protein in adjuvant; LNC were harvested and cultured; and in vitro proliferation assays performed. As observed previously, LNC from rmRP3 fusion protein-immunized mice responded strongly to both rmRP3 and rhRP3 stimulation and to a lesser extent to rmRet TKD protein (Figs. 2 and 3 ). In contrast, LNC from rmRet TKD -immunized mice failed to proliferate in response to stimulation with rmRP3, or the immunizing protein, rmRet TKD (Fig. 3) . LNC from neither immunized mice proliferated when stimulated with a protein control. Given these results, we predicted that only when the RP3 fusion protein was synthesized as a self protein would tolerance be observed.
Tolerance to RP3 fusion protein in transgenic mice
RP3 is the product of two fused self proteins to which T cell tolerance has most likely been induced; however, the above experiments demonstrate LNC and serological reactivity to the novel fusion protein occurs in immunized mice. Unlike wild-type mice, RP3 transgenic mice express the hRP3 fusion gene as a self protein exclusively in the thyroid epithelium (23) by virtue of a bovine thyroglobulin promoter that is known to be active at an early stage of glandular development. To determine whether thyroid-specific expression of RP3 confers T cell tolerance to whole RP3 protein, adult transgenic mice (Ͼ4 mo of age) were immunized with rhRP3 protein, and 2 wk later LNC were harvested. Compared with nontransgenic mice immunized with rhRP3 protein, T cells from immunized RP3 transgenic mice failed to proliferate in response to rhRP3 protein (Fig. 4) . LNC from both rhRP3-immunized RP3 and nontransgenic mice failed to proliferate to an unrelated control protein. Although RP3 mice are reported to develop mild leukocytic infiltrates in their thyroid (25, 26) , thyroid glands resected from immunized and nonimmunized RP3 transgenic mice showed no difference in the degress of infiltration, as determined by histological analysis (not shown).
Preneoplastic thyroid tissue grafts expressing RP3 are not rejected in naive mice
Because injection of purified rRP3 indicated that exogenous exposure of the fusion protein can evoke a strong T cell proliferative response, we next assessed whether RP3-expressing thyroid tissue is also capable of evoking responses in naive mice following organ transplantation. To measure acute immune responses against RP3-expressing preneoplastic thyroid in vivo, thyroid lobes harvested from 4-mo-old RP3 transgenic mice were s.c. transplanted into haplocompatible B6C3F1 and SCID control mice. Thyroid tissue from donor mice at 4 mo of age is composed primarily of small RP3-expressing follicles containing primary and secondary hyperplasia (23) . Three weeks posttransplant (p.t.), 10 of 10 thyroid grafts remained intact (Fig. 5) and functional, as determined by thyroglobulin expression and follicular morphology (not shown). These transplants were free of immune cell infiltration in both B6C3F1 recipients and immunodeficient SCID recipient mice, as determined by histopathological analysis.
Thyroiditis in established transgenic thyroid grafts following infection with RP3, but not wild-type, vaccinia virus
To measure the ability to induce antithyroid immunity mediated by anti-RP3 responses, naive haplocompatible and SCID mice were 3. Self tolerance to a nonfused portion of rmRP3 is preserved. Naive C3H/HeJ mice were immunized twice with either 10 g rmRP3 (gray bars) or 5 g rmRet TKD protein (filled bars), both in adjuvant. One week after final injection, LNC were harvested and assayed for in vitro proliferation in response to stimulation with 1 g/ml rmRP3, 1 g/ml rmRet TKD , or 1 g/ml control bacterial eluate (unrelated proteins). Data are representative of two independent experiments. Mice immunized with rmRet TKD domain did not respond compared with controls, whereas both hRP3 and mRP3 were able to restimulate mRP3-immune lymphocytes (p Ͻ 0.001). rmRP3-immune cells responded strongly to rmRP3 and rmRet TKD in contrast to rmRet TKD -immune cells, which did not significantly respond to these same Ags (p Ͻ 0.0001). Statistical significance was determined by an independent samples t test (Analyze-it).
FIGURE 4. T cell tolerance in RP3 transgenic mice. LNC were harvested from RP3 transgenic mice (filled bars) or nontransgenic littermates (gray bars) 1 wk following a second s.c. immunization with 10 g rhRP3 protein in adjuvant. Cultured LNC were stimulated in vitro with 1 g/ml rhRP3, the same concentration of an unrelated control protein (rTcl1), or with PBS alone (none), and assayed for proliferation. Proliferation of RP3-primed LNC from RP3 transgenic mice was not significantly different from controls. In contrast, cultured LNC proliferated significantly more to hRP3 protein from RP3-primed nontransgenic littermates than from unrelated protein-primed controls or from RP3 transgenic mice (p Ͻ 0.01). Data are representative of three independent experiments. Statistical significance was determined by an independent samples t test (Analyze-it).
s.c. transplanted with a single RP3-expressing transgenic thyroid lobe and monitored for graft rejection for 5 mo. All grafts in recipient mice formed stable and measurable masses (10 of 10), suggesting a lack of complete tissue rejection and resolution (Fig. 5) . To determine whether peripheral T cells are capable of recognizing the graft when stimulated under inflammatory conditions, recipient mice were infected i.v. with 10 7 PFU recombinant vaccinia virus encoding RP3, 10 7 PFU wild-type vaccinia virus, or PBS at 5 mo p.t. Mice were monitored weekly for rejection of established transplants. After 2 mo, minimal reductions in graft size were noted from recombinant virus-infected mice (Ϫ7.79 ϩ/Ϫ 2.21%) compared with wild-type virus-infected mice (ϩ3.17 ϩ/Ϫ 3.45%). To determine whether thyroid transplants were rejected and to measure the degree of leukocyte involvement following immunization, the transplanted RP3 thyroid lobes were resected, embedded, sectioned, and analyzed histopathologically. Examination of transplanted RP3 thyroid lobes from RP3 vaccinia virus-infected mice (Fig. 6 ) revealed thyroiditis with infiltration of neutrophils, monocytes, and lymphocytes in 25-50% of the transplant (Fig. 6C) , whereas transplants from PBS and wild-type vaccinia virus-infected mice remained free of leukocytic infiltration (Fig. 6, A and  B) . Extensive lymphocytic infiltration of the follicles caused significant organ disruption, although noninfiltrated regions of the thyroid transplant remained normal in morphology (Fig. 6C) . Despite widespread thyroiditis, complete destruction and resolution of RP3 thyroid grafts were not observed following single immunization with either recombinant or wild-type virus. The sequential order of thyroid transplant and immunization was not critical because similar results were observed in naive mice vaccinated with recombinant vaccinia virus 2 wk before a transgenic thyroid transplants (not shown).
Rejection of rapidly growing RP3-expressing thyroid tumors in naive mice
Because thyroids from 4-mo-old RP3 transgenic mice are slow growing, rarely metastasize, and remain encapsulated (23) , it was possible that thyroid organ transplants, in contrast to vaccinia virus-infected tissues, were incapable of eliciting a sufficiently strong inflammatory signal for the initiation of an appreciable graft rejection response. Consequently, to derive a strong inflammatory signal from thyroid grafts, we used tumor fragments expressing RP3 protein. RP3 mice that have been crossed to p53 null mutants (RP3 p53Ϫ/Ϫ ) develop large, fast-growing, poorly differentiated thyroid carcinomas (4). Although RP3 expression is eventually lost in these advanced tumors, thyroid tumors from 6-mo-old RP3 p53Ϫ/Ϫ mice still express uniformly detectable levels of RP3, as previously demonstrated (4) . To address the possibility that the inflammatory properties of malignant growth may enhance the induction of antithyroid responses in vivo, 3-mm 3 thyroid tumor fragments from 6-mo-old RP3 p53Ϫ/Ϫ mice were transplanted s.c. into haplocompatible recipient mice and monitored weekly for tumor outgrowth. Whereas 100% of the RP3 p53Ϫ/Ϫ thyroid tumor fragments transplanted into SCID mice grew rapidly, only 23% of tumor fragments transplanted into B6C3F1 recipients grew progressively, as assessed at 3 wk p.t. (Fig. 5) . Histopathological analysis was performed on the remaining thyroid transplants resected from B6C3F1 recipients at 1 mo p.t. Compared with tumors grown in SCID mice, tumor resected from B6C3F1 mice was infiltrated with numerous polymorphonuclear neutrophils and lymphocytes (Fig. 7) .
RP3-specific T cell, but not B cell, responses in tumor-rejecting mice
Leukocyte involvement suggested Ag-specific T cell responses may be elicited during RP3 tumor rejection. To investigate this, 2 mo following tumor transplant, B6C3F1 recipient mice were sacrificed and autopsied to verify the complete rejection of RP3 p53Ϫ/Ϫ thyroid tumor. Complete rejection was confirmed by analysis of the transplant site following specimen embedding, fixation, and H&E staining. Furthermore, if RP3 is a dominant tumor Ag in tumor-rejected recipients, a robust lymphoproliferative response should be detectable by standard proliferation assay. To measure T cell responses to RP3 in these mice, regional and distal lymph nodes were harvested from tumor-rejecting mice, cultured, and assayed in vitro for a proliferative response to serial dilutions of rhRP3 protein.
RP3
p53Ϫ/Ϫ tumor-sensitized LNC proliferated strongly to rhRP3 protein, but not to unrelated control protein stimulation (Fig. 8) . Because RP3 is composed of two widely expressed self proteins, RFG/ARA70 and c-RET, the only unique portion of RP3 in the tumor tissue is the fusion breakpoint region. Therefore, to measure fusion region-specific responses, cultured tumor-rejecting LNC were stimulated with the fusion region-specific peptide in vitro. Similar to rRP3-immune lymphocytes, LNC from tumor-rejecting mice did not proliferate to the fusion region peptide, suggesting that natural processing of this epitope from tumors does not evoke a thyroid-specific immune response. LNC from nonimmunized B6C3F1 mice failed to respond to rRP3, an RP3 fusion region peptide, or an unrelated protein (not shown). To measure the humoral response to RP3 during thyroid tumor rejection, serum was collected from tumor-rejecting mice and assayed for Ag specificity by ELISA. In contrast to the serological reactivity detected in rRP3-immunized mice, Ab responses specific to rhRP3 protein were not detected in serum samples from RP3 p53Ϫ/Ϫ tumor-rejecting B6C3F1 mice, suggesting that Ab reactivity is not required for tumor rejection (Fig. 1C) .
Discussion
In this study, we investigated the immunogenicity of RET/PTC3 (RP3), a novel thyroid tumor-specific fusion protein, frequently expressed in human thyroid cancers and in thyroid epithelial cells of patients afflicted with Hashimoto's thyroiditis. Because no mouse homologue exists to study the role of RP3 in disease, we synthesized a mRP3 protein and studied its immunogenicity in normal and RP3 transgenic mice. Unlike other transgenic models (27, 28) that have used nonphysiological surrogate tumor Ags, RP3 is a somatically activated oncoprotein, formed following DNA damage, and expressed in an exclusive tissue-specific manner in human thyroid epithelium. Because RP3 represents a unique protein, we hypothesized that it would behave as a tumor Ag in naive mice and a self protein in RP3 trangenic mice, and thus assessed its capacity to elicit a response under immunization conditions that would distinguish self from nonself proteins.
Results obtained from proliferation assays demonstrate the specific T cell immunogenicity of RP3 fusion protein when presented by APCs. We predicted that immunity generated against a protein derived from the fusion of two widely expressed self proteins, such as RFG/ARA70 and c-RET, would be directed against the unique fusion region segment of the chimeric molecule because tolerance to the flanking regions would likely occur following T cell development. On the contrary, we found little reactivity to the fusion breakpoint peptide predicted to bind I-E k , suggesting that a nonbreakpoint region of the fusion protein encoded the dominant immunogenic epitope(s). Interestingly, robust T cell responses to the mRet TKD were observed following RP3 immunization consistent with the location of an immunogenic epitope in this region, as predicted by MHC-binding algorithms. Tolerance in normal mice was observed, however, when the self protein parts of RP3 were used as immunogens. These data indicate that an autoimmune response against proteins may occur by a process that increases or alters epitope production following the fusion of two unrelated proteins.
However, how might the formation of a fusion protein lead to such changes in Ag processing? Presumably, folding of the c-RET kinase domain is not altered by fusion to RFG/ARA70, given the preservation of its activity. Thus, one might expect similar handling of this domain by the Ag-processing machinery in the context of both c-RET and RP3, and therefore tolerance to any c-RETderived epitopes generated by processing of RP3. There are several potential explanations for why this is not the case. One factor to consider is the change in subcellular location, from the inner leaflet of the plasma membrane (c-RET) to the cytosol (RP3). This may substantially alter the Ag-processing pathways that are available. For example, both endosomal/lysosomal proteases and the cytosolically located proteasome have been implicated in the processing of cytosolic Ags for class II-restricted presentation (29) . Perhaps c-RET is targeted principally to the endocytic compartment, whereas RP3 is targeted to the proteasome, with the epitopes that are generated in each case being distinct. This scenario presumes endogenous presentation of both proteins (presentation by the cell that expresses the protein), but it may also be that most presentation of c-RET and RP3 requires transfer of the proteins to professional APCs (cross-priming). In this case, both proteins would most likely be presented through the classic endocytic pathway, a possibility that is currently being tested. Even so, variable processing of the carboxyl-terminal domain of RP3 is still a strong possibility, as it has been shown that binding of Ab to an Ag, analogous to fusion of the carboxyl-terminal region of c-RET with the amino-terminal region of RFG/ARA70, significantly alters the efficiency with which particular epitopes are generated (30) . Finally, it should be noted that lysosomal proteases cathepsin B, D, and L are up-regulated in thyroid cancers and in thyroid tissue from patients with autoimmune disease (31, 32) . Thus, it may be a change in the processing machinery rather than a change in the substrate that is responsible for generation of the transformation-associated epitope. Whichever of these mechanisms proves correct, the formation of RP3 predisposes thyroid epithelium to overcome tolerance through the recognition of self epitopes. Future studies will help to resolve the processing mechanism specific for the RP3 fusion protein.
Even though the fusion of two self proteins is an important feature of the immunogenicity of RP3, the malignant state of the RP3-expressing tissue determined whether thyroid-specific immunity could be induced. For example, although direct immunization led to RP3-specific immunity, premalignant thyroidal expression of RP3 alone was not sufficient for the unprimed induction of immunity against thyroid tissue grafts expressing RP3. Although the immunogenic properties of thyroid grafts are different from other organs such as skin (33) , the lack of immune response to RP3-expressing thyroid grafts may be due to insufficient proinflammatory mediator production at the time of priming. Indeed, even strongly immunogenic viral Ags have a tolerizing effect when expressed in skin grafts without coincident inflammation and are immunogenic only following a localized inflammatory reaction (34, 35) . Furthermore, tissue grafts encoding the E7 tumor Ag of human papillomavirus type 16 are rejected more readily when Ag priming occurs in the presence of an LPS-induced inflammatory reaction (36) . Consistent with this idea, we find high level expression of a number of key proinflammatory mediators by developed thyroid carcinomas, but fewer and lower amounts of these mediators in preneoplastic thyroid lesions of RP3 transgenic mice. 4 Early neoplastic lesions may thus represent an immunological crossroad between tolerance to self and immunity to tumor, with direction being determined by the extent and amount of cytokines produced from stressed or transformed cells. In addition to these inflammatory mediators, the state of newly grafted tissue, tumor fragments vs single thyroid lobes excised en bloc, may also influence the effector response because increased cellular apoptosis and necrosis may facilitate Ag uptake and cross-presentation by professional APCs, resulting in thyroid tissue rejection. Even though, in some cases, antitumor Ab may facilitate Ag processing for tumor rejection, humoral responses were not detected in RP3 tumorrejecting mice, a finding not inconsistent with other tumor systems (37) . Even though these data support a T cell-mediated rejection mechanism, they do not explain the reasons for the lack of humoral responses. In addition, thyroid cells expressing RP3 secrete a number of inflammatory cytokines (J. Russell, M. Santoro, and J. L. Rothstein, manuscript in preparation) that may bias immune responses toward T cell immunity; however, future studies will be necessary to understand the strength of this response in vivo.
Previous data have shown frequent expression of RP3 fusion gene at very early stages of cancer (38) and in thyroid tissue of patients with thyroid autoimmune disease, suggesting that this expression may underlie the coexistence of neoplasia (10, 11) and autoimmunity. Studying the early stages of RP3 expression in mouse thyroid tissue will help to evaluate the inflammatory conditions within the organ observed at very early stages following thyroid transformation, but before carcinoma and/or autoimmune disease occurs. This is important because the time frame between cancer initiation and detection can be many years, over which time the immunological landscape of the transformed thyroid may change. This is more apparent when considering the studies presented in this work, which may provide the basis for understanding the widespread effects of how oncogene-altered epithelial cells may evoke immune responses. RP3 expression in thyroid tissue may provide both a strong antigenic and chemotactic stimulus for monocytes and lymphocytes to infiltrate oncogene-expressing tissue in patients with disease-prone MHC backgrounds. Accordingly, this suggests that to evoke an effective immune response against oncogene-expressing tissue, an alteration in the target tissue may be necessary. This change appears following the transition of thyroid tissue from normal to neoplastic, possibly mimicking the proinflammatory effects brought on by immunizing the host with adjuvants or with highly immunogenic viruses. Thus, the expression of RP3 in thyroid tissue of patients with neoplastic thyroid disease supports a model of autoimmunity whereby organ immunogenicity is a consequence of oncogenic transformation, resulting in the development of chronic inflammation.
